Quick Answer
Coherus Oncology, Inc. reported Cash And Cash Equivalents At Carrying Value of $88.88 million for the year ending 2025.
- Coherus Oncology, Inc. showed a decrease of -29.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Coherus Oncology, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,056.7%.
- Historical annual values: Fiscal year 2025: $88.88 million | Fiscal year 2024: $125.99 million | Fiscal year 2023: $102.89 million | Fiscal year 2022: $63.55 million | Fiscal year 2021: $417.20 million | Fiscal year 2020: $541.16 million | Fiscal year 2019: $177.67 million | Fiscal year 2018: $72.36 million | Fiscal year 2017: $126.91 million | Fiscal year 2016: $124.95 million | Fiscal year 2015: $158.23 million | Fiscal year 2014: $150.39 million | Fiscal year 2013: $39.55 million | Fiscal year 2012: $14.55 million | Fiscal year 2011: $7.68 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: